These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
75 related articles for article (PubMed ID: 25926282)
1. An Efficient, Noniterative Method of Identifying the Cost-Effectiveness Frontier. Suen SC; Goldhaber-Fiebert JD Med Decis Making; 2016 Jan; 36(1):132-6. PubMed ID: 25926282 [TBL] [Abstract][Full Text] [Related]
2. The Probabilistic Efficiency Frontier: A Framework for Cost-Effectiveness Analysis in Germany Put into Practice for Hepatitis C Treatment Options. Mühlbacher AC; Sadler A Value Health; 2017 Feb; 20(2):266-272. PubMed ID: 28237207 [TBL] [Abstract][Full Text] [Related]
3. Using propensity scores to estimate the cost-effectiveness of medical therapies. Indurkhya A; Mitra N; Schrag D Stat Med; 2006 May; 25(9):1561-76. PubMed ID: 16158412 [TBL] [Abstract][Full Text] [Related]
5. Calculating and Interpreting ICERs and Net Benefit. Paulden M Pharmacoeconomics; 2020 Aug; 38(8):785-807. PubMed ID: 32390067 [TBL] [Abstract][Full Text] [Related]
6. Optimal cost-effectiveness decisions: the role of the cost-effectiveness acceptability curve (CEAC), the cost-effectiveness acceptability frontier (CEAF), and the expected value of perfection information (EVPI). Barton GR; Briggs AH; Fenwick EA Value Health; 2008; 11(5):886-97. PubMed ID: 18489513 [TBL] [Abstract][Full Text] [Related]
7. Health technology assessment in the cost-disutility plane. Eckermann S; Briggs A; Willan AR Med Decis Making; 2008; 28(2):172-81. PubMed ID: 18356312 [TBL] [Abstract][Full Text] [Related]
8. Probabilistic analysis of cost-effectiveness models: choosing between treatment strategies for gastroesophageal reflux disease. Briggs AH; Goeree R; Blackhouse G; O'Brien BJ Med Decis Making; 2002; 22(4):290-308. PubMed ID: 12150595 [TBL] [Abstract][Full Text] [Related]
12. [Economic analyses of health care. Cost benefit analyses promote better use of resources]. Kristiansen IS Tidsskr Nor Laegeforen; 1990 Aug; 110(18):2377-81. PubMed ID: 2120789 [TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis: role and implications. Marsden G; Wonderling D Phlebology; 2013 Mar; 28 Suppl 1():135-40. PubMed ID: 23482549 [TBL] [Abstract][Full Text] [Related]
14. Probabilistic One-Way Sensitivity Analysis with Multiple Comparators: The Conditional Net Benefit Frontier. McCabe C; Tramonti G; Sutton A; Hall P; Paulden M Pharmacoeconomics; 2021 Jan; 39(1):19-24. PubMed ID: 33225423 [TBL] [Abstract][Full Text] [Related]
15. Guidelines for performing a pharmacoeconomic analysis. Jolicoeur LM; Jones-Grizzle AJ; Boyer JG Am J Hosp Pharm; 1992 Jul; 49(7):1741-7. PubMed ID: 1621734 [TBL] [Abstract][Full Text] [Related]
16. Environmental cost-effectiveness analysis in intertemporal natural resource policy: evaluation of selective fishing gear. Kronbak LG; Vestergaard N J Environ Manage; 2013 Dec; 131():270-9. PubMed ID: 24184529 [TBL] [Abstract][Full Text] [Related]
17. Using cost-effectiveness/cost-benefit analysis to allocate health resources: a level playing field for prevention? Phillips KA; Hotlgrave DR Am J Prev Med; 1997; 13(1):18-25. PubMed ID: 9037338 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness in healthcare: complexity of the equation. Archambault A J Can Diet Assoc; 1988; 49(2):80-5. PubMed ID: 10312528 [TBL] [Abstract][Full Text] [Related]
19. Approaches for Efficiently Detecting Frontier Cells in Robotics Exploration. Quin P; Nguyen DDK; Vu TL; Alempijevic A; Paul G Front Robot AI; 2021; 8():616470. PubMed ID: 33732732 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis in relation to budgetary constraints and reallocative restrictions. Adang E; Voordijk L; Jan van der Wilt G; Ament A Health Policy; 2005 Oct; 74(2):146-56. PubMed ID: 16153475 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]